Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Safety Assessment of Influenza Vaccination for Neurological Outcomes Among Older Adults in Japan: A Self-Controlled Case Series Study.
Pharmacoepidemiol Drug Saf
January 2025
Department of Clinical Epidemiology & Health Economics, School of Public Health, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
Purpose: To assess adverse neurological risks following influenza vaccination in older adults.
Methods: Using a linked database of healthcare administrative claims data and vaccination records from an urban city in Japan (April 1, 2014, to March 31, 2020), we conducted an observational study utilizing a self-controlled case series design. We identified individuals aged ≥ 65 years who experienced adverse neurological outcomes, defined as hospitalizations related to epilepsy, paralysis, facial paralysis, neuralgia, neuritis, optic neuritis, migraine, extrapyramidal disorders, Guillain-Barre syndrome, or narcolepsy.
Evaluating Adverse Drug Reactions, Their Reporting Rates and Their Impact on Attitudes Toward Pharmacotherapy Among Female Patients with Schizophrenia: Insights and Implications from a Cross-Sectional Study.
Healthcare (Basel)
December 2024
Department of Pharmacy, University of Split School of Medicine, Soltanska 2A, 21000 Split, Croatia.
Background/objectives: Schizophrenia is a chronic psychiatric disorder usually managed with antipsychotics, which can cause adverse drug reactions (ADRs) that may impact patients' attitudes toward their treatment, as well as treatment adherence. This study aimed to assess the influence of ADRs and other factors on treatment attitudes among female patients with schizophrenia.
Methods: A cross-sectional study was conducted at the Vrapče Psychiatry Clinic with 109 female schizophrenia patients.
Effectiveness and safety of aripiprazole oral solution in the acute treatment of schizophrenia in Chinese patients.
BMC Psychiatry
December 2024
The National Clinical Research Center for Mental Disorders, Beijing Key Laboratory of Mental Disorders, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, China.
Background: This study investigates the effectiveness and safety of aripiprazole oral solution in Chinese patients with schizophrenia.
Methods: This was a multicenter, single-arm phase IV study involving 134 patients in China in the acute stage of schizophrenia from May 2021 to July 2022. The patients received aripiprazole oral solution 10 - 30 mg/d for 12 weeks.
Prevalence, correlates, tolerability-related outcomes, and efficacy-related outcomes of antipsychotic polypharmacy: a systematic review and meta-analysis.
Lancet Psychiatry
December 2024
Department of Psychiatry, Zucker Hillside Hospital, Northwell Health, Glen Oaks, NY, USA; Department of Psychiatry and Molecular Medicine, Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY, USA; Center for Psychiatric Neuroscience, Feinstein Institute for Medical Research, Manhasset, NY, USA; Department of Child and Adolescent Psychiatry, Charité Universitätsmedizin, Berlin, Germany; German Center for Mental Health (DZPG), partner site Berlin, Germany.
Article Synopsis
- Antipsychotic polypharmacy, or the use of multiple antipsychotic medications, is common in clinical practice, but it carries a higher risk of side effects and there's little proof that it works better than using a single medication.
- A systematic review analyzed 517 studies involving over 4.4 million individuals to determine the prevalence and trends of antipsychotic polypharmacy across different mental disorders.
- The findings revealed that 24.8% of individuals were using multiple antipsychotics, with higher rates in those with schizophrenia spectrum disorders and significant regional variations, showing an overall trend of increasing polypharmacy from 1970 to 2023.
Efficacy and tolerability of blonanserin in schizophrenia: A systematic review and meta-analysis of randomized controlled trials.
Schizophr Res
December 2024
Technical University of Munich, School of Medicine and Health, Klinikum rechts der Isar, Department of Psychiatry and Psychotherapy, Munich, Germany; Deutsches Zentrum für Psychische Gesundheit (DZPG), partner site München/Augsburg, Germany. Electronic address:
Background: Blonanserin is approved for treating schizophrenia in Japan, South Korea, India, and China. We aimed to synthesize the efficacy and tolerability of blonanserin compared to other antipsychotics.
Methods: A systematic review and pairwise meta-analysis were conducted using the Cochrane Schizophrenia Group's study-based trial register until January 24, 2024.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!